Prognostic indicators of relapse-free and overall survival in patients with high-risk primary breast cancer following high-dose chemotherapy.

被引：0
|
作者：
Somlo, G
Chu, P
Frankel, P
Chow, W
Forman, S
Leong, L
Margolin, K
Morgan, R
Shibata, S
Yen, Y
Doroshow, J
机构：
[1] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[2] City Hope Comprehens Canc Ctr, Dept Biostat, Duarte, CA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2001年 / 69卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
227
引用
收藏
页码：243 / 243
页数：1
相关论文
共 50 条
  • [41] Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF
    Sanchez, B. C.
    Sundqvist, M.
    Fohlin, H.
    Spyratos, F.
    Nordenskjold, B.
    Stal, O.
    Linderholm, B. K.
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (09) : 1580 - 1587
  • [42] SEQUENTIAL HIGH-DOSE CHEMOTHERAPY (HDCT) AND IMMUNOTHERAPY IN THE ADJUVANT TREATMENT OF HIGH-RISK BREAST CANCER
    Recchia, F.
    Saggio, G.
    Cesta, A.
    Rea, S.
    ANNALS OF ONCOLOGY, 2004, 15 : 21 - 22
  • [43] High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
    Tallman, MS
    Gradishar, WJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1998, 42 (Suppl 1) : S60 - S67
  • [44] Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancer
    Fields, KK
    Elfenbein, GJ
    Perkins, JB
    Ballester, OF
    Goldstein, SC
    Heimenz, JW
    Saez, RA
    Sullivan, DM
    Partyka, JS
    Kronish, LA
    SEMINARS IN ONCOLOGY, 1998, 25 (02) : 1 - 6
  • [45] High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer
    Rodenhuis, S
    Bontenbal, M
    Beex, LVAM
    Wagstaff, J
    Richel, DJ
    Nooij, MA
    Voest, EE
    Hupperets, P
    van Tinteren, H
    Peterse, HL
    TenVergert, EM
    de Vries, EGE
    NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (01): : 7 - 16
  • [46] High-dose chemotherapy and autologous stem cell transplantation as treatment for high-risk breast cancer
    Martin S. Tallman
    William J. Gradishar
    Cancer Chemotherapy and Pharmacology, 1998, 42 : S60 - S67
  • [47] Early relapse and predictors of relapse-free survival in neoadjuvant chemotherapy-treated breast cancer patients
    Martin, Natalie
    Pasztorova, Julia
    Hibell, Isabella
    Wheatley, Duncan
    CANCER RESEARCH, 2022, 82 (04)
  • [48] Protein expression profiling in high-risk breast cancer patients treated with high-dose or conventional dose-dense chemotherapy
    Diallo-Danebrock, Raihanatou
    Ting, Evelyn
    Gluz, Oleg
    Herr, Alexander
    Mohrmann, Svjetlana
    Geddert, Helene
    Rody, Achim
    Schaefer, Karl-Ludwig
    Baldus, Stephan E.
    Hartmann, Arndt
    Wild, Peter J.
    Burson, Michael
    Gabbert, Helmut E.
    Nitz, Ulrike
    Poremba, Christopher
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 488 - 497
  • [49] Tandem high-dose chemotherapy in high-risk primary breast cancer: A multivariate analysis and a matched-pair comparison with standard-dose chemotherapy
    Schneeweiss, A
    Goerner, R
    Hensel, M
    Lauschner, I
    Sinn, P
    Kaul, S
    Egerer, G
    Beldermann, F
    Geberth, M
    Solomayer, E
    Grischke, EM
    Haas, R
    Ho, AD
    Bastert, G
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (06) : 332 - 342
  • [50] p53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support
    Hensel, M
    Schneeweiss, A
    Sinn, HP
    Egerer, G
    Solomayer, E
    Haas, R
    Bastert, G
    Ho, AD
    INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (03) : 290 - 296
12345